AstraZeneca’s Enthusiasm For Vaccines On The Wane
As COVID-19 Nasal Vaccination Trial Falters
As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.
